Skip to main content
Year archive

Enlivex Therapeutics Ltd. — 2023 filings

All 55 regulatory filings released by Enlivex Therapeutics Ltd. (ENLV) in 2023, sourced directly from the official regulator.

55 Filings
2023 Period
2023 filings (55)
Filing Released Lang
Announces Completion of Enrollment of Its Phase II Trial Evaluating Allocetra In Patients With Sepsis
Regulatory Filings
2023-12-20 English
Announces Completion of Enrollment of Its Phase II Trial Evaluating Allocetra In Patients With Sepsis
Report Publication Announcement
2023-12-20 English
Form 6-K- Third Quarter 2023 Financial Results
Interim / Quarterly Report 9M 2023
2023-11-10 English
Form 6-K- Third Quarter 2023 Financial Results
Report Publication Announcement
2023-11-10 English
6K-Court approved The Company’s share repurchase program was approved by Court
Regulatory Filings
2023-11-08 English
6K-Court approved The Company’s share repurchase program was approved by Court
Report Publication Announcement
2023-11-08 English
RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS HELD ON NOVEMBER 2 2023
Declaration of Voting Results & Voting Rights Announcements
2023-11-03 English
RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS HELD ON NOVEMBER 2 2023
Report Publication Announcement
2023-11-03 English
Annual General Meeting of Shareholders to be held on October 26, 2023
Proxy Solicitation & Information Statement
2023-10-27 English
Annual General Meeting of Shareholders to be held on October 26, 2023
AGM Information
2023-10-27 English
The General Meeting of Shareholders was adjourned for one week due to lack of quorum
Regulatory Filings
2023-10-27 English
The General Meeting of Shareholders was adjourned for one week due to lack of quorum
Report Publication Announcement
2023-10-27 English
Form 6-K- a share repurchase program for up to an aggregate amount of $1.5 million of the Company’s outstanding ordinary shares
Regulatory Filings
2023-09-18 English
Form 6-K- a share repurchase program for up to an aggregate amount of $1.5 million of the Company’s outstanding ordinary shares
Report Publication Announcement
2023-09-18 English
NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS To be held on October 26, 202
Proxy Solicitation & Information Statement
2023-09-14 English
NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS To be held on October 26, 202
AGM Information
2023-09-14 English
NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS To be held on October 26, 202
AGM Information
2023-09-14 English
Enlivex Announces Reprioritization Plan and Second Quarter 2023 Financial Results
Regulatory Filings Q2 2023
2023-09-11 English
Enlivex Announces Reprioritization Plan and Second Quarter 2023 Financial Results
Report Publication Announcement
2023-09-11 English
FINANCIAL STATEMENTS As of June 30, 2023
Interim / Quarterly Report H1 2023
2023-09-02 English
FINANCIAL STATEMENTS As of June 30, 2023
Report Publication Announcement H1 2023
2023-09-02 English
Form 6-K -Enlivex Announces Peer-Reviewed Publication in Frontiers in Immunology of Clinical Data Details Resolution of Acute Respiratory Distress Syndrome (ARDS) from two Phase I/II Trials Evaluating
Regulatory Filings
2023-08-02 English
Form 6-K -Enlivex Announces Peer-Reviewed Publication in Frontiers in Immunology of Clinical Data Details Resolution of Acute Respiratory Distress Syndrome (ARDS) from two Phase I/II Trials Evaluating
Report Publication Announcement
2023-08-02 English
Announces Dosing of First Patient Under The Amended Protocol Of Its Phase II trial Evaluating Allocetra™ In Patients With Sepsis
Regulatory Filings
2023-07-31 English
Announces Dosing of First Patient Under The Amended Protocol Of Its Phase II trial Evaluating Allocetra™ In Patients With Sepsis
Report Publication Announcement
2023-07-31 English
Enlivex Announces First Quarter 2023 Financial Results and Provides a Business Update
Earnings Release Q1 2023
2023-06-26 English
Enlivex Announces First Quarter 2023 Financial Results and Provides a Business Update
Report Publication Announcement
2023-06-26 English
Unaudited condensed consolidated financial statements for Enlivex as of March 31, 2023 and December 31, 2022 and for the three month periods ended March 31, 2023 and 2022
Interim / Quarterly Report Q1 2023
2023-06-17 English
Unaudited condensed consolidated financial statements for Enlivex as of March 31, 2023 and December 31, 2022 and for the three month periods ended March 31, 2023 and 2022
Report Publication Announcement
2023-06-17 English
Enlivex Selected for an Elevator Pitch Presentation and two additional Poster Presentations at the 2023 Annual Meeting of the International Society for Cell & Gene Therapy
Regulatory Filings
2023-05-31 English
Enlivex Selected for an Elevator Pitch Presentation and two additional Poster Presentations at the 2023 Annual Meeting of the International Society for Cell & Gene Therapy
Report Publication Announcement
2023-05-31 English
Announces Issuance of European Patent Covering the Use of Allocetra™ to Prevent Cytokine Release Syndrome (CRS) Resulting from CAR T-Cell Therapy
Regulatory Filings
2023-05-08 English
Announces Issuance of European Patent Covering the Use of Allocetra™ to Prevent Cytokine Release Syndrome (CRS) Resulting from CAR T-Cell Therapy
Report Publication Announcement
2023-05-08 English
Enlivex Receives Notice of Allowance for U.S. Patent Application Covering the Use of Allocetra™ in Patients Receiving CAR T-Cell Therapy
Regulatory Filings
2023-04-19 English
Enlivex Receives Notice of Allowance for U.S. Patent Application Covering the Use of Allocetra™ in Patients Receiving CAR T-Cell Therapy
Report Publication Announcement
2023-04-19 English
Appoints Andrew Singer to its Board of Directors
Board/Management Information
2023-04-17 English
Appoints Andrew Singer to its Board of Directors
Report Publication Announcement
2023-04-17 English
FORM 20-F For the fiscal year ended December 31, 2022
Annual Report FY 2022
2023-04-10 English
FORM 20-F For the fiscal year ended December 31, 2022
Report Publication Announcement
2023-04-10 English
Enlivex Announces Tislelizumab Clinical Collaboration, Full Year 2022 Financial Results, and Provides Business Updates
Earnings Release FY 2022
2023-04-04 English
Enlivex Announces Tislelizumab Clinical Collaboration, Full Year 2022 Financial Results, and Provides Business Updates
Report Publication Announcement
2023-04-04 English
Enlivex Announces Clinical Collaboration to Evaluate Combinations of Allocetra and PD-1 Inhibitor Tislelizumab for Patients with Solid Tumors
Regulatory Filings
2023-04-03 English
Enlivex Announces Clinical Collaboration to Evaluate Combinations of Allocetra and PD-1 Inhibitor Tislelizumab for Patients with Solid Tumors
Report Publication Announcement
2023-04-03 English
6-k -FINANCIAL STATEMENTS AS OF DECEMBER 31, 2022
Audit Report / Information FY 2022
2023-04-01 English
6-k -FINANCIAL STATEMENTS AS OF DECEMBER 31, 2022
Report Publication Announcement
2023-04-01 English
Receives Positive DSMB Recommendation and IMOH Clearance to Continue Phase I/II Trial of Allocetra combined with chemotherapy in patients with peritoneal metastases arising from solid cancers
Regulatory Filings
2023-03-20 English
Receives Positive DSMB Recommendation and IMOH Clearance to Continue Phase I/II Trial of Allocetra combined with chemotherapy in patients with peritoneal metastases arising from solid cancers
Report Publication Announcement
2023-03-20 English
Rceives Clearance From Spanish Agency of Medicines and Medical Devices For Treatment of Patients with Advanced Solid Malignancies in the Ongoing Allocetra Phase I/II Clinical Trial
Regulatory Filings
2023-02-23 English
Rceives Clearance From Spanish Agency of Medicines and Medical Devices For Treatment of Patients with Advanced Solid Malignancies in the Ongoing Allocetra Phase I/II Clinical Trial
Report Publication Announcement
2023-02-23 English
וssuance of Israeli Patent Covering the Use of Allocetra™ to Prevent Cytokine Release Syndrome (CRS)
Regulatory Filings
2023-02-15 English
וssuance of Israeli Patent Covering the Use of Allocetra™ to Prevent Cytokine Release Syndrome (CRS)
Report Publication Announcement
2023-02-15 English
Enlivex Announces Positive DSMB Recommendation and IMOH Clearance to Continue Phase I/II Trial of Allocetra in Patients with Advanced Solid Tumors
Regulatory Filings
2023-01-25 English
Enlivex Announces Positive DSMB Recommendation and IMOH Clearance to Continue Phase I/II Trial of Allocetra in Patients with Advanced Solid Tumors
Report Publication Announcement
2023-01-25 English
Receives Authorizations from French and Belgian Regulatory Agencies To Expand Its Phase II Sepsis Clinical Trial Into France and Belgium
Regulatory Filings
2023-01-04 English
Receives Authorizations from French and Belgian Regulatory Agencies To Expand Its Phase II Sepsis Clinical Trial Into France and Belgium
Report Publication Announcement
2023-01-04 English